Description: Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company has research collaboration with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
Home Page: www.medigene.com
Lochhamer Strasse 11
Munich,
82152
Germany
Phone:
49 89 2000 330
Officers
| Name | Title |
|---|---|
| Dr. Selwyn Ho MB BS, MBBS | CEO & Chairman of Executive Management Board |
| Dr. Dolores J. Schendel | Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development |
| Dr. Ernst-Ludwig Winnacker | Co-Founder & Chairman Scientific Advisory Board |
| Dr. Birger Kohlert | Chief Financial Officer |
| Pamela Keck | Vice President of Investor Relations & Corporate Communications |
| Dr. Kirsty Crame M.D. | VP and Head of Clinical Research & Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 87 |